PRECISION Discussion

EUCLID Trial Primary Results Late Breaking Clinical Trial Presentation

EUCLID Discussion

Effect of Evolocumab on Progression of Coronary Atherosclerosis in Statin-Treated Patients: A Placebo-Controlled Intravascular Ultrasound Trial

HOPE-3 Discussion

Ionis-angptl3-lRx, An Antisense Inhibitor To Angiopoietin-like Protein 3 [angptl3] Reduces Plasma Angptl3 And Lipids In Healthy Volunteers With Elevated Triglycerides

Ionis-angptl3-lRx Discussion

PIONEER AF-PCI discussion

Patients at intermediate surgical risk undergoing isolated interventional or surgical aortic valve replacement for severe symptomatic aortic valve stenosis One Year results from the German Aortic Valve Registry (GARY)

GLAGOV Discussion

MILANO-PILOT – Impact of Infusion of an ApoA-I HDL Mimetic on Regression of Coronary Atherosclerosis in Acute Coronary Syndrome Patients: The MILANO-PILOT Study

GLAGOV – Effect of Evolocumab on Progression of Coronary Atherosclerosis in Statin-Treated Patients: A Placebo-Controlled Intravascular Ultrasound Trial

Short- and Long-Term Effect of Immediate Vasodilator Therapy in Acutely Decompensated Heart Failure: Results of the TRUE-AHF Trial

TRUE-AHF Discussion

Diabetes management with cardiovascular focus

Risk reductions with LDL-level lowering. Role of PCSK9 Inhibitors in CV Prevention.

Familial Hypercholesterolemia: Early Atherosclerosis: Epidemiology and Risk Factors

Aldosterone Targeted NeuroHormonal CombinEd with Natriuresis TherApy in Heart Failure

Management of Atrial Fibrillation (Joint Session with the Heart Rhythm Society) - Who Should Get an Antiarrhythmic Drug and Which Drug to Use

RE-VERSE-AD – Idarucizumab For Dabigatran Reversal: Updated Results Of The Re-verse Ad Study

Conclusions About Intensive Blood Pressure Management - Global implications of SPRINT Trial

Importance of Non-HDL Cholesterol

The Safety and Tolerability of CSL112

Intensive Blood Pressure Management - Why? How?; Moving forward with SPRINT trial

Novelties about anticoagulant therapy

Results of GLAGOV Study

Implications of SPRINT Trial in clinical practice

Management of atrial fibrillation with NOACs in everyday clinical practice

APEX Substudy results - Betrixaban a New Factor Xa inhibitor vs. Enoxaparin in Stroke risk reduction

PIONEER Study results - Rivaroxaban or Warfarine Use in Atrial Fibrillation After Coronary Intervention